Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors

被引：0
|
作者：
Jeffrey L. Cummings
Sylvia Askin-Edgar
机构：
[1] University of California,Department of Neurology, School of Medicine
[2] University of California,Psychiatry & Biobehavioral Sciences, School of Medicine
[3] UCLA School of Medicine,Reed Neurological Research Center
来源：
CNS Drugs | 2000年 / 13卷
关键词：
Dementia With Lewy Body; Rivastigmine; Tacrine; MMSE Score; Galantamine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Alzheimer’s disease is a dementing illness, the risk of which increases markedly with age. It is estimated that it consumes $US90 billion annually. Alzheimer’s disease is marked by an expanding cholinergic deficit, with a direct relationship between the degree of cholinergic dysfunction and the cognitive impairment. Substantial research continues to be focused on the development of newer and better medications, in particular acetylcholinesterase inhibitors (AChEIs), to compensate for the cholinergic deficit.
引用
收藏
页码：385 / 395
页数：10
相关论文
共 50 条
  • [31] Behavioral and molecular evidence for psychotropic effects in L-theanine
    Wakabayashi, Chisato
    Numakawa, Tadahiro
    Ninomiya, Midori
    Chiba, Shuichi
    Kunugi, Hiroshi
    PSYCHOPHARMACOLOGY, 2012, 219 (04) : 1099 - 1109
  • [32] Behavioral and molecular evidence for psychotropic effects in l-theanine
    Chisato Wakabayashi
    Tadahiro Numakawa
    Midori Ninomiya
    Shuichi Chiba
    Hiroshi Kunugi
    Psychopharmacology, 2012, 219 : 1099 - 1109
  • [33] PSYCHOTROPIC EFFECTS OF ESTROGEN - EVIDENCE FROM STUDIES ON POSTMENOPAUSAL WOMEN
    SHERWIN, BB
    NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) : S27 - S28
  • [34] VASCULAR EFFECTS OF ACETYLCHOLINESTERASE INHIBITORS IN THE RABBIT EYE - A STUDY WITH FASCICULIN AND PHYSOSTIGMINE
    SILVEIRA, R
    STJERNSCHANTZ, J
    JOURNAL OF OCULAR PHARMACOLOGY, 1992, 8 (02): : 129 - 137
  • [35] Kinetics of muscarinic reduction of IsAHP in hippocampal neurons:: Effects of acetylcholinesterase inhibitors
    Zhang, Y
    Carlen, PL
    Zhang, L
    JOURNAL OF NEUROPHYSIOLOGY, 1997, 78 (06) : 2999 - 3007
  • [36] Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease
    Kaushik, Vinod
    Smith, Sarah Toombs
    Mikobi, Emmanuel
    Raji, Mukaila A.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2018, 33 (02): : 73 - 85
  • [37] Effects of acetylcholinesterase inhibitors on sleep architecture in Alzheimer's disease patients
    Loredo, JS
    Linn, M
    Liu, L
    Greenfield, D
    Marler, M
    Corey-Bloom, J
    Ancoli-Israel, S
    SLEEP, 2003, 26 : A349 - A349
  • [38] Potential cardioprotective effects of acetylcholinesterase inhibitors in patients with Alzheimer's disease
    Rampa, L.
    Gaspardone, C.
    Fiore, G.
    Romagnolo, D.
    Cerutti, A.
    Santangelo, R.
    Magnani, M.
    Piscazzi, G.
    Sgherzi, G.
    Filippi, M.
    Margonato, A.
    Fragasso, G.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [39] Does use of acetylcholinesterase inhibitors prevent or delay the prescribing of psychotropic medications in people with dementia? Analyses of the Swedish dementia registry (SveDem)
    Tan, Edwin C. K.
    Johnell, Kristina
    Bell, J. Simon
    Garcia-Ptacek, Sara
    Fastbom, Johan
    Nordstrom, Peter
    Eriksdotter, Maria
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 424 - 425
  • [40] PSYCHOTROPIC EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS - WHICH ARGUMENTS
    MESURE, G
    FALLET, A
    CHEVALIER, JF
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 1995, 21 (05): : 609 - 614
12345